Effect of the endothelin type A–selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: Results of a prospective pilot study

Lignende værker

• Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis
  af: Arefiev, Kait, et al.
  Udgivet: (2011)
• Treatment of digital ulcers in systemtic sclerosis with endothelin-1 receptor antagonist (bosentan)
  af: V. Grattagliano, et al.
  Udgivet: (2011-09-01)
• Digital Ischemic Loss in Systemic Sclerosis
  af: Marvi, Umaima, et al.
  Udgivet: (2010)
• Management of digital vasculopathy in systemic sclerosis: benefits of multiple courses of endothelin-1 receptor antagonists
  af: Ngcozana, Tanaka, et al.
  Udgivet: (2014)
• Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey
  af: Linos, Eleni, et al.
  Udgivet: (2013)